PDCD1 and neoplasm: Though tumor PD-L1 expression has been used as a predictive biomarker for anti-PD-1/PD-L1 immunotherapy, more than 50% of tumors with strong PD-L1 expression did not respond to PD-1/PD-L1 inhibitors [10,52,53].